Corient Private Wealth LP Invests $3.17 Million in Vir Biotechnology, Inc. $VIR

Key Points

• Corient Private Wealth LP purchased 310,548 shares of Vir Biotechnology worth approximately $3.17 million, representing about 0.18% of the company. Institutional investors collectively own 65.32% of Vir’s stock.
• Vir reported quarterly revenue of $238.95 million and EPS of $0.47, exceeding analyst estimates of $135.88 million in revenue and $0.33 EPS. Despite significant year-over-year revenue growth, the company posted a negative net margin of 638.88%.
• Analyst sentiment is generally positive, with a consensus “Moderate Buy” rating and an average price target of $21.57, compared with the stock’s reported price of $11.63.

Corient Private Wealth LP purchased a new position in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 310,548 shares of the company's stock, valued at approximately $3,165,000. Corient Private Wealth LP owned approximately 0.18% of Vir Biotechnology at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. Fiduciary Financial Advisors bought a new stake in shares of Vir Biotechnology in the 2nd quarter worth $29,000. Raymond James Financial Inc. bought a new position in shares of Vir Biotechnology during the second quarter valued at $35,000. UMB Bank n.a. lifted its holdings in shares of Vir Biotechnology by 1,418.7% during the fourth quarter. UMB Bank n.a. now owns 7,062 shares of the company's stock valued at $43,000 after purchasing an additional 6,597 shares in the last quarter. CWM LLC boosted its position in shares of Vir Biotechnology by 23.0% during the fourth quarter. CWM LLC now owns 8,804 shares of the company's stock valued at $53,000 after buying an additional 1,646 shares during the last quarter. Finally, Nano Cap New Millennium Growth Fund L P purchased a new stake in shares of Vir Biotechnology during the fourth quarter valued at $60,000. 65.32% of the stock is owned by hedge funds and other institutional investors.

Vir Biotechnology Stock Performance

Shares of NASDAQ:VIR opened at $11.63 on Wednesday. The stock's 50-day simple moving average is $9.65 and its two-hundred day simple moving average is $9.37. The stock has a market capitalization of $1.97 billion, a price-to-earnings ratio of -6.25 and a beta of 1.62. Vir Biotechnology, Inc. has a 52-week low of $4.75 and a 52-week high of $11.74.

Vir Biotechnology (NASDAQ:VIR - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.47 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.33 by $0.14. Vir Biotechnology had a negative net margin of 638.88% and a negative return on equity of 29.99%. The company had revenue of $238.95 million for the quarter, compared to the consensus estimate of $135.88 million. During the same quarter last year, the firm posted ($0.80) earnings per share. The firm's revenue was up 19582.5% compared to the same quarter last year. As a group, equities analysts forecast that Vir Biotechnology, Inc. will post -1.84 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have weighed in on VIR. Wall Street Zen raised Vir Biotechnology from a "sell" rating to a "hold" rating in a research report on Saturday, August 8th. Morgan Stanley set a $25.00 price target on shares of Vir Biotechnology in a report on Thursday, August 6th. Leerink Partners lifted their price target on shares of Vir Biotechnology from $20.00 to $21.00 and gave the stock an "outperform" rating in a research note on Wednesday, June 3rd. Weiss Ratings reiterated a "sell (d-)" rating on shares of Vir Biotechnology in a research note on Wednesday, July 8th. Finally, HC Wainwright reissued a "buy" rating on shares of Vir Biotechnology in a report on Monday, August 10th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $21.57.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company's pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.

Want to see what other hedge funds are holding VIR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source